C Group + E Group
Phase 2/3UNKNOWN 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Pneumonia
Conditions
Nosocomial Pneumonia
Trial Timeline
Mar 1, 2012 → Dec 1, 2016
NCT ID
NCT01796717About C Group + E Group
C Group + E Group is a phase 2/3 stage product being developed by Pfizer for Nosocomial Pneumonia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01796717. Target conditions include Nosocomial Pneumonia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01796717 | Phase 2/3 | UNKNOWN |
Competing Products
7 competing products in Nosocomial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin; imipenem/cilastitin | Johnson & Johnson | Phase 3 | 77 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Ceftolozane/Tazobactam | Merck | Phase 1 | 33 |
| vancomycin monotherapy + daptomycin monotherapy | Novartis | Phase 3 | 77 |
| linezolid | Pfizer | Phase 3 | 76 |
| ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) | Pfizer | Phase 3 | 76 |
| Veronate | Bristol Myers Squibb | Pre-clinical | 22 |